RAD51 and neoplasm: As reported by Neijenhuis et al. and Huang et al. miR-107, miR-222 and miR-103 regulate the DDR and sensitize tumor cells to PARP inhibitors in breast cancer cell lines, targeting RAD51 and impairing HR (90, 91).